Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06826612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

StatusRecruiting
PhasePhase 1/2
Started2025-02-21
View on ClinicalTrials.gov ↗

Amendment history

2026-04-29
minor
Study Status, Contacts/Locations v9
Study sitescontacts updated at 3 of 5 sites
2026-04-14
minor
Study Identification, Study Status, Contacts/Locations v8
Study sitescontacts updated at 1 of 5 sites
2026-01-26
minor
Study Status, Contacts/Locations v7
Study sites3→5
2025-12-16
minor
Study Identification, Study Status, Sponsor/Collaborators v6
Lead sponsorSpark Therapeutics, Inc.→Hoffmann-La Roche
2025-10-22
minor
Study Status, Oversight v5
Re-verified, no change to tracked fields
Show 4 earlier versions
2025-07-02
minor
Study Status, Contacts/Locations v4
Study sites2→3
2025-05-19
minor
Study Identification, Study Status, Contacts/Locations v3
Study sites1→2
Study titlerevised
A Randomized Study of SPK-10001 Gene Therapy in Participants withWith Huntington's Disease
2025-03-19
minor
Study Identification, Study Status, Oversight, Contacts/Locations v2
Study sitescontacts updated at 1 of 1 site
Study titlerevised
A Randomized Study of SPK-10001 Gene Therapy in Participants Withwith Huntington's Disease
2025-02-25
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-02-28→confirmed 2025-02-21
Study sites0→1
2025-02-10
minor
Original filing
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Trial Details
NCT Number NCT06826612
Lead Sponsor Hoffmann-La Roche
Conditions Huntington Disease
Enrollment 53 participants
Start Date 2025-02-21
Primary Completion 2035-01-12 (estimated)
Study Completion 2035-01-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-05